Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

NCT02306291 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT06652685 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562 ·Status: RECRUITING ·Phase: PHASE3

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

NCT06667973 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

NCT06713837 ·Status: RECRUITING ·Phase: PHASE3

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

NCT03096496 ·Status: UNKNOWN

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

NCT03435341 ·Status: COMPLETED

Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients

NCT01570465 ·Status: TERMINATED

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

NCT04460950 ·Status: RECRUITING

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

NCT06235801 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

NCT06379360 ·Status: RECRUITING ·Phase: PHASE2

"InDACtion" vs "3+7" Induction in AML

NCT02172872 ·Status: UNKNOWN ·Phase: PHASE3

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649 ·Status: RECRUITING ·Phase: PHASE2

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

NCT06764459 ·Status: RECRUITING

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

NCT00003131 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

NCT00052299 ·Status: COMPLETED ·Phase: PHASE3

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

NCT03789981 ·Status: ACTIVE_NOT_RECRUITING

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

NCT00006122 ·Status: COMPLETED ·Phase: PHASE2

Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations

NCT07254611 ·Status: COMPLETED

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

NCT04454580 ·Status: UNKNOWN

A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

NCT06058741 ·Status: ACTIVE_NOT_RECRUITING

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

NCT03751917 ·Status: UNKNOWN

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

NCT05520567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

NCT00003673 ·Status: COMPLETED ·Phase: PHASE2

RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.

NCT05127798 ·Status: UNKNOWN